newsfilter
← Latest News
Business Wire·

4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update

- Topline data from Part A of asthma study expected in 2H 2021 - Discontinuation of enrollment in Phase II study of MRx-4DP0004 for the treatment of hospitalized patient with COVID-19 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical compa